268 related articles for article (PubMed ID: 24256111)
1. Twists and turns of determining amyloid type and amyloid-related organ damage: discordance and clinical skepticism in the era of proteomic typing.
Kaul E; Pilichowska M; Vullaganti M; Madan N; Comenzo RL
Amyloid; 2014 Mar; 21(1):62-5. PubMed ID: 24256111
[TBL] [Abstract][Full Text] [Related]
2. Pathology and Proteomics-Based Diagnosis of Localized Light-Chain Amyloidosis in Dogs and Cats.
Kadota A; Iwaide S; Miyazaki S; Mitsui I; Machida N; Murakami T
Vet Pathol; 2020 Sep; 57(5):658-665. PubMed ID: 32880234
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.
Klein CJ; Vrana JA; Theis JD; Dyck PJ; Dyck PJ; Spinner RJ; Mauermann ML; Bergen HR; Zeldenrust SR; Dogan A
Arch Neurol; 2011 Feb; 68(2):195-9. PubMed ID: 20937937
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.
Sethi S; Theis JD; Leung N; Dispenzieri A; Nasr SH; Fidler ME; Cornell LD; Gamez JD; Vrana JA; Dogan A
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2180-7. PubMed ID: 20876678
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining.
Paueksakon P; Fogo AB; Sethi S
Hum Pathol; 2014 Jul; 45(7):1445-50. PubMed ID: 24792621
[TBL] [Abstract][Full Text] [Related]
6. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
[TBL] [Abstract][Full Text] [Related]
7. Relationship between monoclonal gammopathy and cardiac amyloid type.
Maleszewski JJ; Murray DL; Dispenzieri A; Grogan M; Pereira NL; Jenkins SM; Judge DP; Caturegli P; Vrana JA; Theis JD; Dogan A; Halushka MK
Cardiovasc Pathol; 2013; 22(3):189-94. PubMed ID: 23102805
[TBL] [Abstract][Full Text] [Related]
8. A stepwise data interpretation process for renal amyloidosis typing by LMD-MS.
Ke M; Li X; Wang L; Yue S; Zhao B
BMC Nephrol; 2022 Apr; 23(1):144. PubMed ID: 35418036
[TBL] [Abstract][Full Text] [Related]
9. AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis.
Manabe S; Iwasaki C; Hatano M; Kametani F; Yazaki M; Nitta K; Nagata M
BMC Nephrol; 2018 Nov; 19(1):337. PubMed ID: 30466387
[TBL] [Abstract][Full Text] [Related]
10. Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites.
Holub D; Flodrova P; Pika T; Flodr P; Hajduch M; Dzubak P
Biomed Res Int; 2019; 2019():3689091. PubMed ID: 30834260
[TBL] [Abstract][Full Text] [Related]
11. [Classification of amyloidosis by laser micro-dissection and mass spectrometry based proteomic analysis].
Shen K; Sun W; Sun J; Sun W; Zhong D; Cao X; Zhou D; Li J
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):99-102. PubMed ID: 25778882
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
Nasr SH; Said SM; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Dispenzieri A; Buadi FK; Vrana JA; Theis JD; Dogan A; Leung N
Kidney Int; 2013 Mar; 83(3):463-70. PubMed ID: 23302715
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
Picken MM
Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
[TBL] [Abstract][Full Text] [Related]
14. Gastric amyloidosis: clinicopathological correlations in 79 cases from a single institution.
Said SM; Grogg KL; Smyrk TC
Hum Pathol; 2015 Apr; 46(4):491-8. PubMed ID: 25649008
[TBL] [Abstract][Full Text] [Related]
15. [Amyloid typing from formalin-fixed paraffin-embedded tissues using LMD-LC-MS/MS system].
Tasaki M; Obayashi K; Ueda M; Ando Y
Rinsho Byori; 2014 Mar; 62(3):291-6. PubMed ID: 24800507
[TBL] [Abstract][Full Text] [Related]
16. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.
Vrana JA; Theis JD; Dasari S; Mereuta OM; Dispenzieri A; Zeldenrust SR; Gertz MA; Kurtin PJ; Grogg KL; Dogan A
Haematologica; 2014 Jul; 99(7):1239-47. PubMed ID: 24747948
[TBL] [Abstract][Full Text] [Related]
17. [New advances in the subtyping of systemic amyloidosis].
Sun WY; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):259-62. PubMed ID: 24598691
[TBL] [Abstract][Full Text] [Related]
18. New insights into systemic amyloidosis: the importance of diagnosis of specific type.
Picken MM
Curr Opin Nephrol Hypertens; 2007 May; 16(3):196-203. PubMed ID: 17420662
[TBL] [Abstract][Full Text] [Related]
19. [Proteomics, a new tool for an accurate typing of amyloidosis].
Colombat M; Holifanjaniaina S; Onifarasoaniaina S; Valleix S; Maisonneuve H; Kahn JE;
Rev Med Interne; 2015 May; 36(5):346-51. PubMed ID: 25544147
[TBL] [Abstract][Full Text] [Related]
20. IgM monoclonal gammopathy with heavy-and-light-chain amyloidosis resembling fibrillary glomerulonephritis determined by tandem mass spectrometry: a case report.
Adachi M; Kitamura M; Muta K; Maekawa A; Uramatsu T; Tadokoro M; Funakoshi S; Hisano S; Kuwahara N; Shimizu A; Mukae H; Nishino T
BMC Nephrol; 2020 May; 21(1):195. PubMed ID: 32448180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
